Literature DB >> 18378995

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.

Celia J A Morgan1, H Valerie Curran.   

Abstract

Cannabis contains various cannabinoids, two of which have almost opposing actions: Delta9-tetrahydrocannabinol (Delta9-THC) is psychotomimetic, whereas cannabidiol (CBD) has antipsychotic effects. Hair samples were analysed to examine levels of Delta9-THC and CBD in 140 individuals. Three clear groups emerged: ;THC only', ;THC+CBD' and those with no cannabinoid in hair. The THC only group showed higher levels of positive schizophrenia-like symptoms compared with the no cannabinoid and THC+CBD groups, and higher levels of delusions compared with the no cannabinoid group. This provides evidence of the divergent properties of cannabinoids and has important implications for research into the link between cannabis use and psychosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378995     DOI: 10.1192/bjp.bp.107.046649

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  80 in total

1.  THC and CBD blood and brain concentrations following daily administration to adolescent primates.

Authors:  S L Withey; J Bergman; M A Huestis; S R George; B K Madras
Journal:  Drug Alcohol Depend       Date:  2020-06-18       Impact factor: 4.492

Review 2.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

3.  Heterogeneity in the composition of marijuana seized in California.

Authors:  James Richard Burgdorf; Beau Kilmer; Rosalie Liccardo Pacula
Journal:  Drug Alcohol Depend       Date:  2011-02-01       Impact factor: 4.492

Review 4.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 5.  Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.

Authors:  Orrin Devinsky; Maria Roberta Cilio; Helen Cross; Javier Fernandez-Ruiz; Jacqueline French; Charlotte Hill; Russell Katz; Vincenzo Di Marzo; Didier Jutras-Aswad; William George Notcutt; Jose Martinez-Orgado; Philip J Robson; Brian G Rohrback; Elizabeth Thiele; Benjamin Whalley; Daniel Friedman
Journal:  Epilepsia       Date:  2014-05-22       Impact factor: 5.864

Review 6.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 7.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

9.  Impact of enzymatic and alkaline hydrolysis on CBD concentration in urine.

Authors:  Mateus M Bergamaschi; Allan Barnes; Regina H C Queiroz; Yasmin L Hurd; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2013-03-15       Impact factor: 4.142

10.  Cannabinoid receptor CB1 mediates baseline and activity-induced survival of new neurons in adult hippocampal neurogenesis.

Authors:  Susanne A Wolf; Anika Bick-Sander; Klaus Fabel; Perla Leal-Galicia; Svantje Tauber; Gerardo Ramirez-Rodriguez; Anke Müller; Andre Melnik; Tim P Waltinger; Oliver Ullrich; Gerd Kempermann
Journal:  Cell Commun Signal       Date:  2010-06-17       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.